Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - valaciclovir hydrochloride, quantity: 556.275 mg (equivalent: valaciclovir, qty 500 mg) - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; povidone; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash. for the treatment of ophthalmic zoster. for the treatment of recurrent herpes labialis (cold sores) for the treatment of clinical episodes of genital herpes simplex infections. for the prevention of recurrent genital herpes. reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with valaciclovir, it is recommended that patients use safer sex practices (see section 4.4 special warnings and precautions for use). prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - valaciclovir, quantity: 500 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; povidone; crospovidone; magnesium stearate; indigo carmine aluminium lake; titanium dioxide; hypromellose; polysorbate 80; macrogol 6000; macrogol 400 - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash. treatment of ophthalmic zoster. treatment of clinical episodes of genital herpes simplex infections. for the prevention of recurrent genital herpes in immunocompromised patients with creatinine clearance of > 15 ml/min. for the reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with valaciclovir, it is recommended that patients use safer sex practices (see precautions). for prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

actavis australia pty ltd - valaciclovir hydrochloride monohydrate; valaciclovir (as hydrochloride monohydrate); valaciclovir hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - valaciclovir hydrochloride monohydrate, quantity: 584 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; macrogol 8000; hypromellose; titanium dioxide; indigo carmine aluminium lake; stearic acid - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash. . for the treatment of ophthalmic zoster. . for the treatment of recurrent herpes labialis (cold sores) . for the treatment of clinical episodes of genital herpes simplex infections. . for the prevention of recurrent genital herpes in immunocompromised patients. . prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - valaciclovir hydrochloride monohydrate, quantity: 1168 mg - tablet, film coated - excipient ingredients: stearic acid; macrogol 8000; titanium dioxide; hypromellose; colloidal anhydrous silica - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash. . for the treatment of ophthalmic zoster. . for the treatment of recurrent herpes labialis (cold sores) . for the treatment of clinical episodes of genital herpes simplex infections. . for the prevention of recurrent genital herpes in immunocompromised patients. . prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - valaciclovir, quantity: 500 mg - tablet, film coated - excipient ingredients: magnesium stearate; povidone; crospovidone; microcrystalline cellulose; indigo carmine aluminium lake; titanium dioxide; hypromellose; polysorbate 80; macrogol 6000; macrogol 400 - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash. treatment of ophthalmic zoster. treatment of clinical episodes of genital herpes simplex infections. for the prevention of recurrent genital herpes in immunocompromised patients with creatinine clearance of > 15 ml/min. for the reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with valaciclovir, it is recommended that patients use safer sex practices (see precautions). for prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Malta - English - Medicines Authority

wockhardt uk limited ash road north, wrexham, ll13 9uf, united kingdom - aciclovir - tablet - aciclovir 800 mg - antivirals for systemic use

Ireland - English - HPRA (Health Products Regulatory Authority)

syri limited, t/a thame laboratories - aciclovir - oral suspension - 400/5 mg/ml - aciclovir

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

wockhardt uk ltd - aciclovir - oral tablet - 200mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sterwin medicines - aciclovir - oral tablet - 200mg